IP Library Granted Patent US 11,268,072
Granted Patent B2
US 11,268,072 · App. 16/510,643 · Granted Mar 8, 2022

Composition of matter: engineering of

Inventors: Sarah Gruszka (Cambridge, MA); Jason Holder (Swampscott, MA)
Assignee: THE CHARLES STARK DRAPER LABORATORY, INC.
C12N7/00C12N15/70C12Q1/18C12Q1/70C12N2795/10021C12N2795/10031C12N2795/10221C12N2795/10231C12N2795/10243
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,268,072
App. No.
16/510,643
Granted
Mar 8, 2022
Kind
B2
Abstract

The present disclosure provides compositions including recombinant K1E bacteriophages, methods for making the same, and uses thereof. The recombinant K1E bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.

Claims (10)

1. A method for making a linear recombinant K1E bacteriophage genome of SEQ ID NO: 3 in vitro comprising

(a) contacting a non-recombinant K1E bacteriophage genome of SEQ ID NO: 1 comprising a single PflF1 recognition site with PflF1 in vitro under conditions where PflF1 cleaves the PflF1 recognition site to produce a cleaved linear non-recombinant K1E bacteriophage genome; and

(b) recombining in vitro the cleaved linear non-recombinant K1E bacteriophage genome with a heterologous nucleic acid of SEQ ID NO: 2 in the presence of 5′-3′ exonuclease, a DNA polymerase, and a DNA ligase in an in vitro DNA assembly reaction under conditions to produce an in vitro generated linear recombinant K1E bacteriophage genome of SEQ ID NO: 3, wherein the in vitro DNA assembly reaction is devoid of biological extracts,

wherein the cleaved linear non-recombinant K1E bacteriophage genome comprises a first cleaved linear bacteriophage genomic fragment and a second cleaved linear bacteriophage genomic fragment,

wherein the heterologous nucleic acid comprises a 5′ flanking region that is homologous to the 3′ end of the first cleaved linear bacteriophage genomic fragment, and a 3′ flanking region that is homologous to the 5′ end of the second cleaved linear bacteriophage genomic fragment,

wherein the 5′ flanking region and the 3′ flanking region of the heterologous nucleic acid do not comprise the single PflF1 recognition site,

and

wherein the in vitro generated linear recombinant K1E bacteriophage genome of SEQ ID NO: 3 is capable of producing non-endogenous bioluminescent protein that is functionally active when transformed into a bacterial host cell.

2. The method of claim 1 , further comprising transforming the in vitro generated linear recombinant K1E bacteriophage genome in a bacterial host.

3. The method of claim 2 , wherein the bacterial host is a non-natural bacterial host cell or a natural bacterial host cell for K1E bacteriophage.

Continuity (4)
Division 16204817 · Nov 29, 2018
Continuation 15908235 · Feb 28, 2018
Provisional Application 62539932 · Aug 1, 2017
Related Publication 20190330599A1 · Oct 31, 2019
Cited By (1)
US 12,419,204